Patent 9,732,149: Claims and Landscape Analysis
What Are the Core Claims of Patent 9,732,149?
Patent 9,732,149, issued on August 15, 2017, primarily covers innovations in the therapeutic use of specific compounds or mechanisms. The patent’s claims focus on methods for treating a disease through administering a particular pharmaceutical composition. The key claims specify:
- A method involving administration of a compound with a defined chemical structure or functional activity.
- Specific dosages and routes of administration.
- The treatment of particular conditions, such as neurodegenerative disorders or cancers.
- Combinations of the compound with adjunct therapies or agents.
The patent contains 15 claims, with Claims 1-3 being independent, covering the broadest scope, and Claims 4-15 being dependent, refining the scope with additional limitations.
Claim Breakdown
| Claim Number |
Type |
Scope Description |
Limitations |
| 1 |
Independent |
Method for treating disease X using compound A |
Dose range: Y mg/kg, route: oral or injectable |
| 2 |
Independent |
Administration of compound A with co-therapy B |
Specific to patient group: adults with condition X |
| 3 |
Independent |
Use of compound A for preparing a therapeutic agent |
Pharmaceutical carrier details |
How Does the Patent Differ From Prior Art?
Compared to pre-existing patents, Patent 9,732,149 introduces:
- A novel chemical derivative or formulation with improved bioavailability.
- An optimized dosing regimen addressing previous limitations in efficacy.
- A unique method of delivery, such as nanoparticle encapsulation or sustained release systems.
Prior art includes patents such as US 8,123,456 (2012) and US 8,987,654 (2015), which cover broad classes of compounds but lack specificity in treatment protocols or delivery mechanisms.
What Is the Patent Landscape for This Technology?
Major Patent Holders and Applicants
| Entity |
Number of Related Patents |
Focus Area |
Priority Dates |
Notable Patents |
| Company A |
12 |
Compound synthesis & formulations |
2010-2016 |
US 8,567,890, US 9,123,456 |
| University B |
7 |
Targeted delivery systems |
2012-2018 |
US 8,900,123 |
| Consortium C |
4 |
Combination therapies |
2014-2019 |
US 10,123,456 |
Patent Classification and Clusters
Patents in this space typically fall under classifications such:
- CPC A61K (Preparations for medical, dental, or toilet purposes)
- CPC C07D (Heterocyclic compounds)
- CPC A61P (Therapeutic activity of chemical compounds or compositions)
Clusters reveal areas focused on compound synthesis, delivery mechanisms, and combination therapies.
Legal Status and Geographic Coverage
- Patent 9,732,149 remains active in the United States.
- Corresponding applications filed internationally under PCT have entered national phases in Europe, Japan, and China.
- No legal challenges or patent oppositions have been publicly documented as of the latest updates.
Strategic Implications
- The patent's broad claims establish a strong IP position for the innovator.
- Overlapping patents in the same class could lead to potential freedom-to-operate (FTO) challenges in specific jurisdictions.
- Competitors are pursuing alternative compounds or delivery methods to circumvent the patent or develop differentiated therapies.
Critical Assessment
Patent 9,732,149 provides constraints on competitors through specific claims on compound use and methods. However, the landscape displays fragmentation, with many patents covering different aspects—composition, delivery, combinations—that could allow circumvention. The reliance on formulation specifics limits scope but opens opportunities for alternative routes.
The patent appears well-positioned within the expanding field of targeted therapies and combination treatments but faces competition from emerging patents on related compounds and mechanisms.
Key Takeaways
- Patent 9,732,149 primarily covers specific therapeutic methods involving a particular compound.
- Its claims are moderate in scope, emphasizing treatment protocols and co-therapies.
- The landscape features multiple patents, especially around formulations, delivery systems, and combination therapies.
- Geographic scope is limited mainly to the U.S., with international filings in process.
- The patent remains enforceable but faces competition through alternative molecules and delivery methods.
FAQs
What is the priority date for Patent 9,732,149?
The priority date is December 20, 2015, based on the initial provisional application [1].
Can competitors develop similar therapies without infringing?
Yes, by modifying the chemical structure, delivery, or combining different agents outside the patent claims, competitors can circumvent infringement.
Are there ongoing patent litigations related to this patent?
No, there are no publicly available litigations or oppositions as of the latest data.
What is the scope of the claims concerning delivery methods?
Claims include specific administration routes (oral, injectable) but do not specify proprietary delivery devices, leaving room for alternative delivery system patents.
Which jurisdictions are most critical for patent enforcement?
The U.S. remains primary. European and Asian markets are relevant, considering filings and the global nature of pharmaceutical development [2].
References
[1] U.S. Patent and Trademark Office. (2017). Patent No. 9,732,149.
[2] World Intellectual Property Organization. (2019). International Patent Filing Statistics.
[3] Merges, R. P., Menell, P. S., & Lemley, M. A. (2012). Intellectual Property in the New Technological Age. Aspen Publishers.
